Latest Updates in Oncology

The medical industry only thrives if they have access to enhanced treatment methodologies, prevention care, and all-over aspects to reduce the rising cancer curve. This results in researchers from around the world to study and implement some of these technologies.

The following represents updates and new technologies to treat most cases of cancer all over the world.

Breast Cancer

The American Society of Breast Surgeons issued the risk of developing lymphedema after a breast cancer surgery can be reduced by avoiding lymph node dissection. It has proved to be the only preventive measure.
The US Food and Drug Administration approved adjuvant abemaciclib in patients with hormone receptor-positive, node-positive breast cancer, HER2-negative benefits were sustained in the latest 27 months of observation both concerning invasive disease-free survival and distant recurrence-free survival.
According to the Comprehensive Cancer Center and the Austrian Breast and Colorectal Cancer Study Group (ABCGS) in Vienna, Palbociclib CoLlaborative Adjuvant study (PALLAS) did not exhibit a significant improvement in the survival process when palbociclib were added to adjuvant endocrine therapy over endocrine therapy in patients with early hormone receptor-positive, HER-2 negative breast cancer.

An analysis shows 14,000 HER2-positive breast cancer patients found that the addition of trastuzumab to chemotherapy improved 10-year recurrence risk by 9 percent and breast cancer mortality by over 6 percent. These were long-term outcomes from documented trials of HER2-positive breast cancer patients.

Endocrine Tumors

Adrenocortical carcinoma (ACC) is rare in pediatric patients. However, a single-arm study was conducted on over 80 pediatric patients with ACC. An outcome of five-year overall long-term survival rates was found; patients with stage I, II, III success rates scored 79-95%, and stage IV patients showed a benefit of 16%.
Chimeric antigen receptor (CAR) T-cell therapy combined in antibody-drug conjugate was taken on; a patient’s T cell (an immune system cell) was used for reprogramming and targeting cancer cells.
Neuroendocrine neoplasms (NENs) can arise in most organs and are widely distributed throughout our bodies. NENs classification and nomenclature were uneasy and confusing in the past. Older classifications were bound to tumors arising from specific organs in the system. Now NENs are classified as G1, G2 which were formerly called carcinoid tumors.

Cervical Cancer

An investigation showed that 3 trials in over 600 cervical cancer patients received first-line chemotherapy for recurrent, consistent, or metastatic cervical cancer. Patients who received pembrolizumab instead of a placebo improved median progression-free survival and overall survival rates. Those patients receiving first-line chemotherapy only for recurrent or metastatic cervical cancer are now suggested pembrolizumab.
A new revelation has come along, intensity-modulated radiation therapy (IMRT) has been estimated to be more effective against 3D conformal radiation therapy (3D-CRT) for patients with adjuvant radiation for their cervical cancer.
US food and Drug Administration has approved tisotumab vedotin (an antibody-drug conjugate used to treat cervical cancer) due to its success in a single-arm, open-label study on 101 patients with metastatic or recurrent cervical cancer progressed with chemotherapy, the drug was associated with a 24% response rate and 7% complete response.
In a trial, random patients with locally advanced cervical cancer were assigned standard cisplatin-based chemoradiation instead of concurrent chemoradiation, which is the standard treatment. Those patients who received cisplatin-based chemoradiation experienced similar five-year overall survival.

Skin Cancer

Nivolumab plus ipilimumab is now considered an acceptable treatment alternative for patients with systemic therapy-naive with metastatic melanoma and asymptotic untreated Central Nervous System metastases. An analysis of phase II trial was carried out on 100 patients, a median follow-up of 34 months, intracranial objective and complete response rates were found to be 54% and 33%, respectively, and three-year OS was found to be 72%.
At St. Jude Children’s hospital, a genetic tweaking on regulatory T cells in mice with melanoma and colon adenocarcinoma has been discovered to be rapidly clearing the tumor cell. Targeting a pathway led to reduced tumor growth in mice, and blocking the pathway showed no effect on regulatory T cells or their overall function.
Based on data from a randomized phase III trial, one year of adjuvant immunotherapy using a single-agent PD-1 inhibitor has been recommended to patients with resected high-risk melanoma, but long-term outcomes are not known. The data suggested an improvement in relapse-free survival and was better sanctioned compared with high-dose of interferon alfa-2b or ipilimumab.

In conclusion

Cancer doctors find technologically advanced ways to treat patients with cancer by carrying out trials, creating new ways of studying and using drugs, teaming up with engineers, and making technology more convenient. The above information can provide recommendations and new options for the patients.

However, it is recommended to consult your doctor and find the best treatment for a specific health condition. Dr. Manish Singhal is the best cancer doctor in Delhi NCR.

We offer the best treatment in all kinds of treatment, including chemotherapy, intensive protocols, immunotherapy, hormonal therapy, and medical care of patients, including online video call consultation and assisted chemotherapy at home.

Dr. Manish Singhal has been working since 2010. His experience and deep knowledge also recognize him as the cancer specialist in Noida. Consider consulting us before it’s late. Give us a call on +91 9971 347 203, calling hours 10:30 AM to 8:30 AM. Drop us an email at info@cancerconsultindia.com.